CINECA IRIS Institutional Research Information System

GRIGGIO, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.659
EU - Europa 1.551
AS - Asia 614
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
SA - Sud America 5
Totale 4.890
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.633
CN - Cina 437
IT - Italia 326
SE - Svezia 232
IE - Irlanda 211
AT - Austria 153
UA - Ucraina 133
FR - Francia 114
DE - Germania 99
FI - Finlandia 65
DK - Danimarca 52
IN - India 35
KR - Corea 33
PL - Polonia 33
SN - Senegal 31
VN - Vietnam 27
GB - Regno Unito 26
SG - Singapore 26
CA - Canada 25
BY - Bielorussia 22
HK - Hong Kong 19
NL - Olanda 18
RU - Federazione Russa 17
BE - Belgio 16
CH - Svizzera 13
EU - Europa 10
UZ - Uzbekistan 10
AU - Australia 9
ES - Italia 8
JP - Giappone 6
ZA - Sudafrica 6
GR - Grecia 4
IR - Iran 4
RO - Romania 4
TH - Thailandia 4
ID - Indonesia 3
AR - Argentina 2
CZ - Repubblica Ceca 2
EG - Egitto 2
NG - Nigeria 2
PH - Filippine 2
PK - Pakistan 2
TR - Turchia 2
TW - Taiwan 2
BW - Botswana 1
CO - Colombia 1
HU - Ungheria 1
IL - Israele 1
LU - Lussemburgo 1
MK - Macedonia 1
MX - Messico 1
PE - Perù 1
SA - Arabia Saudita 1
UY - Uruguay 1
Totale 4.890
Salva come PNG Salva come JPEG
Città #
Chandler 546
Beijing 301
Dublin 210
Ann Arbor 154
Vienna 153
Ashburn 147
Nyköping 115
Jacksonville 110
Dearborn 104
Fairfield 102
Torino 93
Houston 80
Wilmington 73
Medford 71
Princeton 62
Woodbridge 59
Fremont 53
Villeurbanne 52
San Mateo 50
Seattle 48
Florence 33
Redwood City 31
Washington 28
Warsaw 26
Cambridge 25
Dong Ket 18
Pisa 18
New York 17
Turin 16
Brussels 15
Hangzhou 15
Hefei 15
Toronto 13
Chennai 12
Guangzhou 12
Boston 11
Milan 11
Chengdu 10
Düsseldorf 10
Nanjing 10
Norwalk 10
Boardman 9
Linden 9
Rotterdam 9
Oerlikon 8
Paris 8
Codogno 7
Falls Church 7
Phoenix 7
Piemonte 7
Provo 7
Shanghai 7
Central District 6
Guiyang 6
Hong Kong 6
Munich 6
Rome 6
San Diego 6
San Jose 6
Singapore 6
Wayne 6
Casorzo 5
Changsha 5
Kunming 5
Liverpool 5
Ottawa 5
Seoul 5
Volpago Del Montello 5
Canelli 4
Erlangen 4
Helsinki 4
Leawood 4
Mortara 4
Nanchang 4
Pune 4
Shenyang 4
Upper Marlboro 4
Wuhan 4
Adelaide 3
Balingen 3
Bologna 3
Cape Town 3
Changchun 3
Dallas 3
Des Moines 3
Grugliasco 3
Heidelberg 3
Jaipur 3
Jakarta 3
Jinan 3
Johannesburg 3
Limoges 3
Philadelphia 3
San Francesco 3
Swindon 3
Tianjin 3
Tokyo 3
Abuja 2
Appiano Gentile 2
Bresso 2
Totale 3.216
Salva come PNG Salva come JPEG
Nome #
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 276
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 269
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 189
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 173
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 151
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 128
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 127
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 119
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 112
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 103
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 100
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 97
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 93
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 92
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 91
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 89
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 89
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 88
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 85
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 84
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 84
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 81
null 80
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 79
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 79
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 77
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 72
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 70
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance 69
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 67
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells 66
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells 65
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 64
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs 64
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 62
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 61
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 58
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 58
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 58
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 58
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib 57
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 56
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 56
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 54
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 53
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia 49
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 46
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia 45
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 43
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 35
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges 35
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells 33
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 33
The mevalonate pathway as a metabolic target to circumvent multidrug-resistance in chronic lymphocytic leukemia cells (CLL) 24
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia 8
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? 2
Totale 5.067
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.472
article - articoli 0
book - libri 0
conference - conferenze 9.387
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.859
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019190 0 0 0 0 0 0 0 0 0 62 71 57
2019/2020721 21 22 34 96 40 107 80 42 49 91 58 81
2020/2021776 73 70 34 41 126 39 44 70 59 33 105 82
2021/2022891 34 10 32 53 57 17 109 52 19 100 258 150
2022/20231.245 127 139 37 152 106 294 72 73 121 45 48 31
2023/2024428 63 97 41 24 21 105 10 51 5 11 0 0
Totale 5.067